<DOC>
	<DOC>NCT01294553</DOC>
	<brief_summary>An open label, multi-centre, non-interventional post-marketing surveillance to monitor the safety and/or efficacy of rosiglitazone/metformin administered in Korean Diabetic patients according to the prescribing information</brief_summary>
	<brief_title>An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance to Monitor the Safety and/or Efficacy of AVANDAMET Between June 2004 and January 2010</brief_title>
	<detailed_description>An open label, multi-centre, non-interventional post-marketing surveillance to monitor the safety and/or efficacy of rosiglitazone/metformin administered in Korean Diabetic patients according to the prescribing information</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Inclusion criteria Subjects administered with rosiglitazone/metformin as an adjunct to diet and exercise for the treatment of type2 diabetes mellitus Subjects who the investigator believes that they can and will comply with the requirements of the protocol and follow the administration regimen Subjects administered with rosiglitazone/metformin following the locally approved prescribing information Exclusion criteria Subjects with previous history of hypersensitivity to rosiglitazone and/or metformin or any other ingredient Subjects with previous history of lactic acidosis, renal disease or renal dysfunction, hepatic dysfunction, cardiogenic shock, heart failure, myocardial infarction, pulmonary infarction and any other status with stomach upset Subjects with type 1 diabetes mellitus Subjects with acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma Subjects with severe infection, pre/post surgery, severe trauma Subjects with malnutrition, inanition, emaciation, pituitary insufficiency, adrenal insufficiency Subjects undergoing radiologic studies involving intravascular administration of iodinated contrast materials</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
</DOC>